Oct 16th 2012 - Edison Investment Research today published a report on EpiCept Corporation entitled "No Pain, No Gain". In summary, the report says:
EpiCept’s investment case centres on rapidly finding a development/commercial partner for AmiKet, its topical product for chemotherapy-induced peripheral neuropathy. It is also seeking a new partner for Azixa, to which it recently regained all rights. The company has cash until Q113, following the recent sale of Ceplene rights, but its share price remains depressed by financial concerns. Nevertheless, the potential upside from an AmiKet deal – which might come about via an M&A transaction – could reward investors. Following the Ceplene transaction, we calculate an rNPV of $29m, approximately three times the current EV.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »